Medtronic Announces TYRX Antibacterial Envelope Trial Results
Monday, May 18, 2015
Source: FDA News
Medtronic’ TYRX antibacterial envelope cuts down on major cardiac device site infections by 80 percent for up to 12 months following implantation, the Irish devicemaker announced Friday at the Heart Rhythm 2015 conference in Boston, Mass.
Cardiac implantable electronic device infections are increasing and have been linked with serious illness, mortality and high costs, the company says. During a series of multicenter clinical trials, Medtronic tested the envelope for infection-reducing CIED efficacy.